-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target

Benzinga·01/08/2026 21:51:11
語音播報
Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:COYA) with a Buy and maintains $14 price target.